Pennsylvania HB2267 allows secondary school students with pancreatic insufficiency or cystic fibrosis to possess and self-administer prescribed.
Pennsylvania HB2267 amends the Public School Code of 1949 to allow secondary school students with pancreatic insufficiency or cystic fibrosis to possess and self-administer prescribed pancreatic enzyme replacement therapy in school. The bill requires parents or guardians to provide a signed order from a health care practitioner, a written request, and acknowledgments from the school nurse and student. The school entity must adopt a policy allowing possession and self-administration of the therapy, ensuring it is stored in a readily accessible place if not self-carried by the student.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.